Phase 1 Prostate cancer trials recruiting now

All Prostate cancer trials, every phase

Other phases for Prostate cancer

Phase 1 Prostate cancer trials

• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
  NCT07189871 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
  NCT07145177 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
  NCT07219147 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• 3D1015 Injection for Patients With mCRPC
  NCT07537010 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• 64Cu-GRIP B in Patients With Advanced Malignancies
  NCT05888532 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
  NCT04868604 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 7 locations
• A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
  NCT07711184 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: Male · 7 locations
• A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
  NCT06863272 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 82 locations
• A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
  NCT07103018 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 13 locations
• A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
  NCT07198633 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
  NCT07407283 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 85 Years · Sex: Male · 2 locations
• A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer
  NCT07689656 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer
  NCT07135102 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults
  NCT07149831 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
  NCT07258407 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 7 locations
• A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
  NCT07255664 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy
  NCT06044025 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: Male · 1 location
• A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
  NCT07488923 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer
  NCT07735377 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer
  NCT06970119 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
  NCT06826768 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
  NCT07543055 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 2 locations
• A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
  NCT05932862 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 32 locations
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 107 locations
• A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
  NCT07292168 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
  NCT06785636 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
  NCT07533708 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT06879041 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 16 locations
• A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer
  NCT07600554 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 2 locations
• A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
  NCT06736054 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• A Phase I Trial of A-CAR032 in Participants With mCRPC
  NCT07344311 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 5 locations
• A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
  NCT04633252 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 110 Years · Sex: Male · 1 location
• A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
  NCT07226986 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 22 locations
• A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
  NCT06085664 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
  NCT04729114 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 25 locations
• A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
  NCT06906471 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: Male · 2 locations
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
  NCT05800665 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 26 locations
• A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
  NCT07567846 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 5 locations
• A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
  NCT06689163 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT07719361 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 10 locations
• A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
  NCT07730021 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study of DB-1310 in Advanced/Metastatic Solid Tumors
  NCT05785741 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 72 locations
• A Study of DM002 in Patients With Advanced Solid Tumors
  NCT06751329 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
  NCT07189403 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
  NCT06926283 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 4 locations
• A Study of DXC014 in Patients With Advanced Solid Tumors.
  NCT07177937 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
  NCT06782555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
  NCT06990880 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
  NCT07277270 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
  NCT06568094 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: Male · 2 locations
• A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
  NCT05740956 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  NCT07503808 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 45 locations
• A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
  NCT07082920 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 6 locations
• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
  NCT06095089 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
  NCT07746713 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 3 locations
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• A Study of LY4257496 in Participants With Cancer (OMNIRAY)
  NCT07114601 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Study of MHB048C in Patients With Advanced Solid Tumors
  NCT07192120 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of MT-4561 in Patients With Various Advanced Solid Tumors
  NCT06943521 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
  NCT03460977 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 84 locations
• A Study of NX-1607 in Adults With Advanced Malignancies
  NCT05107674 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
  NCT06395519 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
  NCT07319871 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
  NCT05818683 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 15 locations
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
  NCT05652686 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
  NCT06531499 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: Male · 21 locations
• A Study of SHR-4394 Injection in Subjects With Prostate Cancer
  NCT06783829 · Phase: Phase 1 · Ages: 18 Years to 85 Years · Sex: Male · 1 location
• A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
  NCT07705334 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
  NCT07567521 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
  NCT07259213 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
  NCT06457919 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 12 locations
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  NCT04104776 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 160 locations
• A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
  NCT07244341 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer
  NCT07096128 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 3 locations
• A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors
  NCT07661641 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT07581184 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 4 locations
• A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06067841 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 15 locations
• A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
  NCT06155084 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 27 locations
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
  NCT06440005 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
  NCT07339267 · Phase: Phase 1 · Ages: 18 Years to 85 Years · Sex: Male · 1 location
• A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
  NCT07181473 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
  NCT06609005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 22 locations
• A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
  NCT07570979 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 3 locations
• A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
  NCT07540572 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 11 locations
• A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
  NCT07192614 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 26 locations
• A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
  NCT04503265 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
  NCT06830850 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 11 locations
• A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
  NCT05125016 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 14 locations
• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
  NCT03972657 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
  NCT07336446 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 18 locations
• AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
  NCT07285694 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 9 locations
• ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
  NCT07414940 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
  NCT05113537 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
  NCT07206056 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 35 locations
• Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
  NCT05413850 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 21 locations
• Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer
  NCT05646550 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
  NCT05000294 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location

Showing 100 of 231 recruiting trials.

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.